Multiple Myeloma Pipeline 2025: Groundbreaking Clinical Advancements by 75+ Global Leaders - DelveInsight | Featuring CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, Tene

With Multiple Myeloma reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Multiple Myeloma pipeline comprises 75+ pharmaceutical and biotech companies actively developing 80+ therapeutic candidates targeting Multiple Myeloma. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Multiple Myeloma Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Multiple Myeloma Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Multiple Myeloma Drug Development @ https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Multiple Myeloma Pipeline Report

DelveInsight's Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
In April 2024, approved for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. This approval was based on data from the Phase 3 CARTITUDE-4 study, which demonstrated a 59% reduction in the risk of disease progression or death compared to standard therapies.
In March 2024, an FDA advisory panel unanimously backed the expanded use of Carvykti® as an earlier treatment for patients with multiple myeloma. However, there was mixed support for Abecma®, with only eight out of eleven members in favor of its earlier use.
Key Multiple Myeloma companies such as CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others are evaluating new drugs for Multiple Myeloma to improve the treatment landscape.
Promising Multiple Myeloma pipeline therapies in various stages of development include Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, and others.

Multiple Myeloma Overview:

Multiple myeloma (MM) is a disorder involving the clonal proliferation of plasma cells, resulting in an abnormal rise in monoclonal immunoglobulins. If left uncontrolled, the excessive growth of these plasma cells can cause damage to various organs. This damage typically becomes evident through clinical signs such as hypercalcemia, kidney impairment, anemia, or bone pain associated with lytic bone lesions.

Download the Multiple Myeloma sample report to know in detail about the Multiple Myeloma treatment market @ https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple Myeloma Pipeline Analysis
The Multiple Myeloma pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Multiple Myeloma Market.

Categorizes Multiple Myeloma therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Multiple Myeloma drugs under development based on:

Stage of development

Multiple Myeloma Route of administration

Target receptor

Monotherapy vs. combination therapy

Multiple Myeloma Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Multiple Myeloma Licensing agreements

Funding and investment activities supporting future Multiple Myeloma market advancement.

Unlock key insights into emerging Multiple Myeloma therapies and market strategies here: https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple Myeloma Emerging Drugs

Zevorcabtagene Autoleucel: Carsgen Therapeutics

Zevorcabtagene Autoleucel (Zevor-cel, R&D code: CT053) is an autologous, fully human CAR T-cell therapy targeting B-cell maturation antigen (BCMA) for treating relapsed/refractory multiple myeloma (R/R MM). In October 2022, China's National Medical Products Administration (NMPA) accepted its New Drug Application (NDA) and granted it priority review status. Zevor-cel is anticipated to receive NMPA approval for R/R MM treatment by late 2023 or early 2024. In January 2023, CARsgen and Huadong Medicine formed a partnership to commercialize Zevor-cel in mainland China. Since then, both companies have been collaborating closely to facilitate the approval process and prepare for the drug's market launch in China.

Descartes 08: Cartesian Therapeutics

Descartes-08 is an autologous RNA-modified CAR T-cell therapy targeting BCMA. It is created through mRNA transfection to express the anti-BCMA CAR for a specific, limited duration. Descartes-08 expresses the anti-BCMA CAR for about one week, which helps reduce the risk of uncontrolled cell growth. The therapy produces inflammatory cytokines in response to myeloma cells and demonstrates strong cytolytic activity against myeloma cells, even in the presence of bone marrow stromal cells that protect myeloma, proliferation-inducing ligands, or drug resistance such as IMiDs. The extent of cell destruction is linked to how long the anti-BCMA CAR is expressed, indicating a time-limited activity. Early clinical trials have shown that Descartes-08 is safe and well-tolerated in patients with MG and multiple myeloma. The therapy is currently in Phase II development for treating multiple myeloma.

GC012F: Gracell Biotechnology Shanghai Co., Ltd.
CID-103: CASI Pharmaceuticals
STI-1492: Sorrento Therapeutics

Multiple Myeloma Pipeline Therapeutic Assessment

Multiple Myeloma Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Multiple Myeloma By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Multiple Myeloma Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Multiple Myeloma Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Multiple Myeloma therapies and key Multiple Myeloma companies: https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Multiple Myeloma Current Treatment Patterns
4. Multiple Myeloma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple Myeloma Late-Stage Products (Phase-III)
7. Multiple Myeloma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple Myeloma Discontinued Products
13. Multiple Myeloma Product Profiles
14. Multiple Myeloma Key Companies
15. Multiple Myeloma Key Products
16. Dormant and Discontinued Products
17. Multiple Myeloma Unmet Needs
18. Multiple Myeloma Future Perspectives
19. Multiple Myeloma Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Multiple Myeloma pipeline reports offerings: https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.